Literature DB >> 12356687

Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation.

Katsuaki Hoshino1, Tsuneyasu Kaisho, Tomio Iwabe, Osamu Takeuchi, Shizuo Akira.   

Abstract

Toll-like receptor (TLR) can activate dendritic cells (DC) through common signaling pathways requiring a cytoplasmic adapter, MyD88. However, the signaling is differentially regulated among TLR family members. TLR4 can activate MyD88-deficient bone marrow-derived DC (BMDC), and lead to induction of IFN-inducible genes and up-regulation of co-stimulatory molecules such as CD40, implying that the MyD88-independent signaling pathway functions downstream of TLR4. Because these effects can also be induced by type I IFN, we have analyzed whether type I IFN is involved in TLR4-induced responses. In response to lipopolysaccharide (LPS), IFN-beta gene expression was augmented in both wild-type and MyD88-deficient BMDC. Expression of all IFN-inducible genes except immune-responsive gene 1 (IRG1) was abolished and CD40 up-regulation was decreased in LPS-stimulated BMDC lacking either IFN-alpha/beta receptor (IFN-alpha/betaR) or signal transducer and activator of transcription 1 (STAT-1). Similar to the LPS response, TLR9 signaling can also induce expression of IFN-beta and IFN-inducible genes, and up-regulation of CD40. However, all these effects were MyD88 dependent. Thus, in TLR4 signaling, IFN-beta expression can be induced either by the MyD88-dependent or -independent pathway, whereas, in TLR9 signaling, it is dependent on MyD88. In CpG DNA-stimulated DC, expression of IFN-inducible genes except IRG1 was dependent on type I IFN signaling as in LPS-stimulated DC. However, in contrast to TLR4 signaling, TLR9 signaling requires type I IFN signaling for CD40 up-regulation. Taken together, this study demonstrates differential involvement of type I IFN in TLR4- and TLR9-induced effects on DC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356687     DOI: 10.1093/intimm/dxf089

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  89 in total

1.  Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Authors:  Kyle I Happel; Mingquan Zheng; Erana Young; Lee J Quinton; Euan Lockhart; Alistair J Ramsay; Judd E Shellito; Jill R Schurr; Gregory J Bagby; Steve Nelson; Jay K Kolls
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  Optimal CD8 T-cell response against Encephalitozoon cuniculi is mediated by Toll-like receptor 4 upregulation by dendritic cells.

Authors:  Elizabeth M Lawlor; Magali M Moretto; Imtiaz A Khan
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

3.  Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells.

Authors:  Maria Eugenia Ariza; Rupal Ramakrishnan; Narendra P Singh; Ashok Chauhan; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Biol Chem       Date:  2010-10-29       Impact factor: 5.157

4.  Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance.

Authors:  Thomas B Thornley; Nancy E Phillips; Britte C Beaudette-Zlatanova; Thomas G Markees; Kapil Bahl; Michael A Brehm; Leonard D Shultz; Evelyn A Kurt-Jones; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 5.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 6.  ACOD1 in immunometabolism and disease.

Authors:  Runliu Wu; Feng Chen; Nian Wang; Daolin Tang; Rui Kang
Journal:  Cell Mol Immunol       Date:  2020-06-29       Impact factor: 11.530

7.  Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect.

Authors:  Tae-Young Lee; Yang-Hyun Kim; Sun-Woo Yoon; Jai-Chul Choi; Jai-Myung Yang; Chul-Joong Kim; John T Schiller; Moon-Hee Sung; Haryoung Poo
Journal:  Cancer Immunol Immunother       Date:  2009-03-18       Impact factor: 6.968

Review 8.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 9.  Food Fight: Role of Itaconate and Other Metabolites in Antimicrobial Defense.

Authors:  Harding H Luan; Ruslan Medzhitov
Journal:  Cell Metab       Date:  2016-09-13       Impact factor: 27.287

10.  Antiviral-activated dendritic cells: a paracrine-induced response state.

Authors:  Antonio V Bordería; Boris M Hartmann; Ana Fernandez-Sesma; Thomas M Moran; Stuart C Sealfon
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.